Patient description: The patient is a 24-year-old man who has had type 1 diabetes for 11 years. He presents to the emergency room with hyperglycemia and concern for possible diabetic ketoacidosis after not taking his insulin for 3 days. The patient reports that he is currently homeless and has lost his supply of insulin, syringes, glucometer, and glucose testing supplies. The patient states that at the time of his initial diagnosis with type 1 diabetes he was hospitalized with a glucose value >1000 mg/dL. At the time, he was experiencing polyuria, polydipsia, and polyphagia. He reports that he has been on insulin since the time of his diagnosis, and he has never been prescribed oral agents for diabetes management. Most recently, he has been using insulin glargine 55 units once daily, and insulin aspart sliding scale 3 times daily. The patient has had previous episodes of diabetic ketoacidosis, for which he was hospitalized. With this episode of hyperglycemia, he is not experiencing any nausea, vomiting, or abdominal discomfort, and he appears well. His lab studies showed: A1c: 11.3% Creatinine: 0.9 mg/dL with eGFR >60 mL/min Aspartate aminotransferase (AST): 17 U/L Alanine aminotransferase (ALT): 14 U/L Beta-hydroxybutyrate: 0.1 mmol/L Bicarbonate: 25 mEq/L Anion

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Type 2 Diabetes Mellitus FOR AT 1. Diagnosed with type 2 Diabetes Mellitus, as per Investigator diagnosis 2. HbA1c (DCCT-standard) must be ≥ 9.0% and ≤12% 3. Insulin resistance defined as required daily dose up to 1.5u/kg or a maximum of 200 units insulin per day 4. Aged 20 to 75 years old inclusive 5. On premixed regimen (human or analogue insulin) defined as ≥ 2 injections per day for at least 3 months prior signing the informed consent 6. Ability to comply with technology, according to Investigator's judgment 7. Patients must be willing to undergo all study procedures 8. Female patients of child-bearing potential must be using adequate contraception means as assessed by Investigator FOR AT 1. Diagnosed with type 2 DM, as per Investigator diagnosis 2. HbA1c (DCCT-standard) must be ≥ 9.0% and ≤12% 3. Insulin resistance defined as required daily dose up to 1.5 U/Kg or a maximum of 200 units per day 4. On premixed regimen (human or analogue insulin) defined as ≥ 2 injections per day for at least 3 months prior signing the informed consent 5. Ability to comply with technology, according to Investigator's judgment 6. ≥ 2.5 SMBG per day on average 7. Patients must be willing to undergo all study procedures 8. Female patients of child-bearing potential must be using adequate contraception means as assessed by Investigator  FOR (AT AND 1. Subject has a history (≥ 2 events) of hypoglycemic seizure or hypoglycemic coma within the last 6 months 2. Subject is pregnant as assessed by a pregnancy test with central laboratory, or plans to become pregnant during the course of the study 3. Participation in another interventional clinical study, on-going or completed less than 3 months prior to signature of Patient Informed Consent. 4. Subject has proliferative retinopathy or sight threatening maculopathy 5. Subject has an acute coronary syndrome (myocardial infarction or unstable angina) within 12 months OR coronary artery revascularization by bypass surgery or stenting within 3 months OR a transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 3 months OR hospitalization for heart failure within 3 months or current New York Functional Class III or IV OR current 2nd or 3rd degree heart block OR symptomatic ventricular rhythm disturbances OR thromboembolic disease within the last 3 months OR 6. Subject with renal impairment expressed as estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula < 30 ml/min as demonstrated by the screening central laboratory value at the time of enrollment 7. Subject has taken oral or injectable steroids within the last 30 days. 8. Systolic blood pressure on screening visit is > 180 mmHg 9. Diastolic blood pressure on screening visit is > 110 mmHg 10. Any other disease (eg active cancer under treatment) or condition including abnormalities found on the screening tests, that in the opinion of the Investigator, may preclude the patient from participating in the study 11. Taking any medication prescribed for weight loss 12. Alcohol or drug abuse, other than nicotine, at the Investigator's discretion Use of a Glucagon Like Peptide-1 agonist or pramlintide (Symlin®). Glucagon Like Peptide-1 slows gastric emptying, thereby decreasing the rate of glucose absorption. Pramlintide (Symlin®) is a commercially available analogue of amylin, a synergistic partner to insulin